Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05789316 · ClinicalTrials.gov registry record · NA

Head and Neck Cancer Survivorship Ototoxicity Screening (SOS)

A NA study, sponsored by Washington University School of Medicine.

Completed
Registry status
NA
Development phase
55
Enrollment target

NCT05789316 is a NA study that has completed, run by Washington University School of Medicine. The registered enrollment target is 55 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05789316, a NA study, has completed, sponsored by Washington University School of Medicine.

COMPLETED
Registry status
NA
Development phase
55 participants
Enrollment target

Study Summary

To evaluate the effectiveness, feasibility, acceptability, and appropriateness of an ototoxicity screening protocol among head and neck (H\&N) cancer patients followed in survivorship clinic that received cisplatin-based chemoradiation therapy (CRT).

Interventions

  • OTHER Ototoxicity Screening Protocol

Trial Details

FieldValue
Enrollment Target 55 participants
Start Date 2023-06-06
Est. Completion 2025-11-21
Phase NA

What the Registry Record Tells You About NCT05789316

The ClinicalTrials.gov registry entry for NCT05789316 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Ototoxicity Screening Protocol is the first listed.

NCT05789316 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT05789316 about?

NCT05789316 is a clinical study titled "Head and Neck Cancer Survivorship Ototoxicity Screening (SOS)". To evaluate the effectiveness, feasibility, acceptability, and appropriateness of an ototoxicity screening protocol among head and neck (H\&N) cancer patients followed in survivorship clinic that received cisplatin-based chemoradiation therapy (CRT).

What is the current status of trial NCT05789316?

This trial is currently completed. It is a NA study. The enrollment target is 55 participants. The study started on 2023-06-06. Estimated completion is 2025-11-21.

What interventions are being tested in trial NCT05789316?

The interventions under investigation include: Ototoxicity Screening Protocol (OTHER).

Who is sponsoring clinical trial NCT05789316?

This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.